Genetics: Discovering the Unknown in Breast Cancer

Article

For this month’s episode, we spoke with Katherine Crew, MD, an associate professor of medicine and epidemiology at the Columbia University Herbert Irving Comprehensive Cancer Center. Crew discusses her recent research on genetic testing in young women with breast cancer. While she was happy to see that the testing rates were not much different between ethnic groups, there were some differences when it came to the results.

Crew also offers advice for nurses in discussing genetics with their patients, as well as easing the worry of not knowing what some genetic testing results may mean.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
Image of a woman with shoulder-length black hair wearing headphones and a white sweater
Photo of a woman with brown hair and bangs, surrounded by a blue border
Related Content
Anatomical image of a person with a breast tumor

T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

Tim Cortese
June 11th 2025
Article

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

AI-generated graphic of cancer cells

T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

Chris Ryan
June 2nd 2025
Article

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Line illustration of a breast

Sacituzumab Govitecan/Pembrolizumab Backed as New SOC in PD-L1+ TNBC

Kristi Rosa
May 31st 2025
Article

Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

Anatomical rendering of a breast with a tumor

Vepdegestrant Increases PFS in ESR1-Mutated ER+/HER2- Breast Cancer

Caroline Seymour
May 31st 2025
Article

Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.